Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Rudolf Kaaks

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3751-3929; OpenAlex author ID A5033124357, A5102298120. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2011: 2 papers · 2012: 5 papers · 2013: 2 papers · 2014: 4 papers · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 39

  1. Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. Last author DOI 10.1002/ijc.70581↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Last author DOI 10.3390/cancers17142275↗
  4. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  5. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  6. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Co-author DOI 10.1093/ije/dyab115↗
  7. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  8. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Last author DOI 10.1158/1055-9965.epi-21-0169↗
  9. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  10. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Co-author DOI 10.1007/s10654-019-00559-6↗
  11. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Co-author DOI 10.1158/1055-9965.epi-19-0868↗
  12. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Last author DOI 10.1002/ijc.31900↗
  13. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  14. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  15. Methodological issues in a prospective study on plasma concentrations of persistent organic pollutants and pancreatic cancer risk within the EPIC cohort. Co-author DOI 10.1016/j.envres.2018.11.027↗
  16. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  17. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. Co-author DOI 10.1002/ijc.31367↗
  18. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort. Co-author DOI 10.1002/ijc.31797↗
  19. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  20. Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition… Co-author DOI 10.1002/ijc.30590↗
  21. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Co-author DOI 10.1002/ijc.30790↗
  22. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Co-author DOI 10.1158/1055-9965.epi-17-0075↗
  23. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  24. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  25. Plasma carotenoids, vitamin C, retinol and tocopherols levels and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutritio… Co-author DOI 10.1002/ijc.29175↗
  26. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Co-author DOI 10.2337/db14-1132↗
  27. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  28. Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS d… Co-author DOI 10.1093/carcin/bgu010↗
  29. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Co-author DOI 10.1158/1055-9965.epi-13-0437-t↗
  30. Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study. Last author DOI 10.1158/1055-9965.epi-14-0247↗
  31. Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Co-author DOI 10.1093/annonc/mdt255↗
  32. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Co-author DOI 10.1136/gutjnl-2012-303006↗
  33. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Last author DOI 10.1002/ijc.26244↗
  34. Plasma cotinine levels and pancreatic cancer in the EPIC cohort study. Co-author DOI 10.1002/ijc.26452↗
  35. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. First author DOI 10.1038/bjc.2012.172↗
  36. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Last author DOI 10.1038/bjc.2012.19↗
  37. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Coho… Co-author DOI 10.1158/1055-9965.epi-11-1139↗
  38. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into … Last author DOI 10.1007/s00125-011-2316-0↗
  39. A U-shaped relationship between plasma folate and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Co-author DOI 10.1016/j.ejca.2011.02.007↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Verena Andrea Katzke · 13 shared papers, 2013–2026 · strength 0.94
  2. Malin Sund · 19 shared papers, 2011–2025 · strength 0.79
  3. Federico Canzian · 8 shared papers, 2012–2026 · strength 0.68
  4. Vinciane Rebours · 8 shared papers, 2017–2026 · strength 0.60
  5. Eric J. Duell · 19 shared papers, 2011–2020 · strength 0.60
  6. H. Bas Bueno-de-Mesquita · 18 shared papers, 2011–2020 · strength 0.58
  7. Daniele Campa · 5 shared papers, 2014–2026 · strength 0.52
  8. Elio Ríboli · 15 shared papers, 2011–2020 · strength 0.46
  9. Marta Crous‐Bou · 3 shared papers, 2021–2026 · strength 0.46
  10. Esther Molina‐Montes · 11 shared papers, 2011–2025 · strength 0.44
  11. Paolo Vineis · 14 shared papers, 2011–2019 · strength 0.38
  12. María‐Dolores Chirlaque · 5 shared papers, 2012–2025 · strength 0.32
  13. Weimin Ye · 12 shared papers, 2011–2018 · strength 0.29
  14. Sofia Christakoudi · 2 shared papers, 2021–2025 · strength 0.25
  15. Manuel Gentiluomo · 2 shared papers, 2020–2025 · strength 0.24
  16. Paul Brennan · 4 shared papers, 2017–2020 · strength 0.22
  17. Gabriele Capurso · 2 shared papers, 2017–2025 · strength 0.21
  18. Pietro Ferrari · 4 shared papers, 2013–2020 · strength 0.21
  19. Bas H. Bueno-de-Mesquita · 3 shared papers, 2011–2021 · strength 0.18
  20. Lívia Archibugi · 1 shared paper, 2025 · strength 0.17
  21. Giulia Peduzzi · 1 shared paper, 2025 · strength 0.17
  22. Dagfinn Aune · 3 shared papers, 2017–2020 · strength 0.15
  23. Verena A. Grote · 7 shared papers, 2011–2015 · strength 0.14
  24. Dominique S. Michaud · 7 shared papers, 2011–2013 · strength 0.13
  25. Guri Skeie · 4 shared papers, 2011–2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.